Evidence map›Paper›PMID 34003473›Full record

ArticleTherapeutic innovation & regulatory science2021

Investigator Initiated Clinical Trials (IICTs): A Systematic Search in Registries to Compare the Czech Republic and Portugal in Terms of Funding Policies and Scientific Outcomes.

C Madeira, L Hořavová, F Dos Santos, J R Batuca, K Nebeska, L Součková, C Kubiak, J Demotes, R Demlová, E C Monteiro

Abstract read
In one paragraph

Article in Therapeutic innovation & regulatory science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

C Madeira *European Clinical Research Infrastructure Network (ECRIN), Paris, France.
L Hořavová *Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
F Dos SantosPortuguese Clinical Research Infrastructure Network (PtCRIN), Lisbon, Portugal.
J R BatucaEuropean Clinical Research Infrastructure Network (ECRIN), Paris, France.
K NebeskaEuropean Clinical Research Infrastructure Network (ECRIN), Paris, France.
L SoučkováEuropean Clinical Research Infrastructure Network (ECRIN), Paris, France.
C KubiakEuropean Clinical Research Infrastructure Network (ECRIN), Paris, France.
J DemotesEuropean Clinical Research Infrastructure Network (ECRIN), Paris, France.
R DemlováDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
E C MonteiroPortuguese Clinical Research Infrastructure Network (PtCRIN), Lisbon, Portugal. emilia.monteiro@nms.unl.pt.

Funding

European Regional Development Fund CZECRIN_4 PACIENTY (No. CZ.02.1.01/0.0/0.0/16_013/0001826)Fundação para a Ciência e a Tecnologia Portaria nº 237/2014Large Research infrastructure CZECRIN - LM2015090
6 · The paper itself

Abstract

objectivesClinical trials provide one of the highest levels of evidence to support medical practice. Investigator initiated clinical trials (IICTs) answer relevant questions in clinical practice that may not be addressed by industry. For the first time, two European Countries are compared in terms of IICTs, respective funders and publications, envisaging to inspire others to use similar indicators to assess clinical research outcomes.

methodsA retrospective systematic search of registered IICTs from 2004 to 2017, using four clinical trials registries was carried out in two European countries with similar population, GDP, HDI and medical schools but with different governmental models to fund clinical research. Each IICT was screened for sponsors, funders, type of intervention and associated publications, once completed.

resultsIICTs involving the Czech Republic and Portugal were n = 439 (42% with hospitals as sponsors) and n = 328 (47% with universities as sponsors), respectively. The Czech Republic and Portuguese funding agencies supported respectively 61 and 27 IICTs. Among these, trials with medicinal products represent 52% in Czech Republic and 4% in Portugal. In the first, a higher percentage of IICTs' publications in high impact factor journals with national investigators as authors was observed, when compared to Portugal (75% vs 15%).

conclusionThe better performance in clinical research by Czech Republic might be related to the existence of specific and periodic funding for clinical research, although further data are still needed to confirm this relationship. In upcoming years, the indicators used herein might be useful to tracking clinical research outcomes in these and other European countries.

Indexed as

PolicyCzech RepublicHumansPortugalRegistriesRetrospective StudiesClinical researchClinical research outcomeClinical trialClinical trials registryFundingInvestigator initiated clinical trials

Identifiers

PMID34003473
PMCPMC8332583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.